BioSpace News Archive

ENDRA Life Sciences Inc. (NASDAQ: NDRA), announces that the Chinese National Intellectual Property Administration has issued ENDRA two new patents, Chinese Patent No. ZL 2019 8 00400927 (the ‘927 patent) titled “Method and System for Determining Fractional Fat Content of Tissue,” and Chinese Patent No. ZL 2019 8 00870250 (the ‘250 patent) titled “Radio Frequency Applicator and Thermoacoustic Imaging System Employing the Same”.

Coya Therapeutics, Inc. (“Coya” or the “Company”), today announced David S. Snyder has joined the Company as Chief Financial Officer and Chief Operating Officer.

According to Report, the global subcutaneous drug delivery devices market size is estimated to reach US$ 51.99 billion by 2029 and expanding growth at a CAGR of 9.3% from 2021 to 2030.

As per Precedence Research, the over the counter (OTC) drugs market size is estimated to hit US$ 294.18 billion by 2030 and growing at a CAGR of 6.9% from 2021 to 2030.

The pharmaceutical intermediates market is estimated to worth around US$ 47.1 billion by 2029 and growing at a CAGR of 6.3% from 2021 to 2030.

Precedence Research Predicts, the global oncology market size is expected to worth around US$ 536.01 billion by 2029 from valued at USD 286.04 billion in 2021 and growing at a CAGR of 8.2% from 2021 to 2030.

The global neurovascular devices market size is estimated to worth around US$ 4.33 billion by 2029, poised to grow at a compound annual growth rate (CAGR) of 5.7% during the forecast period 2021 to 2030.

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, issued the following statement in response to the release from Richard Kayne:

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the initiation of a Phase 1 trial evaluating its novel chimeric antigen receptor T-cell (CAR-T) therapy in ovarian cancer.

Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on artificial intelligence (AI)-enabled drug discovery, today announced the dosing of the first patient in a Phase 1 study of AC0176, an orally bioavailable, chimeric degrader molecule designed to target the androgen receptor (AR) with high potency and selectivity.